INBS

Business Context and Reporting Period

Company: Intelligent Bio Solutions Inc. (INBS)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2024
Business Overview: INBS is a medical technology company focused on non-invasive testing solutions. Its primary revenue-generating segment is the Intelligent Fingerprinting (IFP) platform, which uses fingerprint sweat for drug screening. The company also holds a license for the Biosensor Platform Technology (BPT) for point-of-care testing, though this segment is currently in development and generated no revenue.

Key Financial Metrics

Note: Per share data has been retroactively adjusted for a 1-for-12 reverse stock split effective January 26, 2024.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 147.6% year-over-year, driven by the expansion of the customer base in existing markets (UK) and new regions (Australia, New Zealand, South America).
• Margin Expansion: Gross profit margin improved significantly from 25.99% to 45.81%, attributed to economies of scale and increased sales volume.
• Operating Expenses: Total operating expenses decreased slightly to $12.13 million from $13.66 million. This reduction was primarily due to the absence of a $4.16 million goodwill impairment charge recorded in the prior year related to the IFP acquisition.
• Capital Raising: The company raised approximately $14.56 million in net proceeds during the fiscal year through a public offering, a warrant inducement transaction, and a private placement, significantly bolstering cash reserves.
• Government Support: Government support income decreased to $424,776 from $737,628, partly due to an adjustment for a potential refund of an Australian government grant if project milestones are not met.

Guidance, Outlook, Risks, and Contingencies

Outlook and Management Commentary

• FDA Clearance: The company is progressing through its FDA 510(k) clinical study plan for the IFP Drug Screening System. The in-clinic portion of the Pharmacokinetic (PK) study was completed in June 2024, with the full study expected to conclude in Q3 2024. The company targets FDA submission by the end of 2024 and US market entry in 2025.
• Product Development: New assays for ketamine and tramadol have passed the initial design phase. The company is also exploring the expansion of its technology into medical diagnostics (e.g., tumor markers, hormones).
• Licensing Uncertainty: The licensor for the Biosensor Platform Technology (LSBD) has entered liquidation. Intellectual property rights have reportedly reverted to the University of Newcastle. INBS is in early-stage discussions to restructure the licensing agreement, but no timeline has been established.

Risks and Contingencies

• Going Concern: The independent auditor has included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern. Management believes current cash ($6.3 million) may be insufficient to fund operations for the next 12 months without additional financing.
• Internal Controls: The company identified material weaknesses in its internal control over financial reporting, citing a lack of documented policies, insufficient evidence for control performance, and limited accounting personnel.
• Grant Milestones: The company has completed only 4 of 8 milestones for an Australian government grant. An extension was granted until March 2025; failure to meet these milestones could require a refund of the grant.
• Regulatory Approval: Failure to obtain FDA clearance or other regulatory approvals would materially harm the business plan and ability to generate significant revenue in the US market.

Key Facts for Investor Verification

• Liquidity Runway: Verify the sufficiency of the $6.3 million cash balance against the burn rate and the timeline for FDA clearance to assess the risk of dilution from future capital raises.
• BPT Licensing Status: Confirm the outcome of discussions with the University of Newcastle regarding the Biosensor Platform Technology license, as this asset is critical to the company's long-term diversification strategy.
• FDA 510(k) Timeline: Monitor the completion of the full PK study and the subsequent FDA submission date to validate the 2025 US market entry projection.
• Internal Control Remediation: Review progress on remediation plans for the identified material weaknesses in internal controls to ensure future financial reporting reliability.
• Grant Compliance: Track the completion of the remaining 4 milestones for the Australian government grant to avoid potential liability for repayment.